Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge advises TSG on the acquisition of Processkontroll GT

TSG, a European leader in technical services for sustainable mobility solutions and critical energy infrastructure, has acquired Processkontroll GT, a specialist in compressed and liquid gas infrastructure.
June 01, 2026

Vinge has advised Mirova with the financing of the Fågelås, Dållebo, and Boarp wind farms

The financing, provided by Danske Bank and La Banque Postale, consists of multiple facilities totalling approximately EUR 100 million, including, among other things, a long-term amortising loan and guarantee facilities.
June 01, 2026

Vinge has advised Nordion Energi AB in connection with the acquisition of shares in Kalmar Energi

Nordion Energi acquires E.ON Sverige AB’s entire stake in Kalmar Energi and in connection with the completion of such, divest Kalmar Energi’s electricity retail business to Siljansvik AB (publ).
May 29, 2026